Orthocell delivers record FY2026 revenue as US Remplir rollout accelerates

Orthocell reported record quarterly and full-year revenue, highlighting accelerating adoption of its Remplir™ nerve repair device. The update implies improving commercial traction, which should be supportive for the stock, though the magnitude of any guidance or margin change was not provided in the excerpt.

Analysis

Orthocell reported record quarterly and full-year revenue, highlighting accelerating adoption of its Remplir™ nerve repair device. The update implies improving commercial traction, which should be supportive for the stock, though the magnitude of any guidance or margin change was not provided in the excerpt.